Clinical trials: Diffuse Large Cell
Recurrent Adult Diffuse Large Cell Lymphoma
Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
This phase II clinical trial is studying how well selumetinib works in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT01278615
- Testing
- Laboratory Biomarker Analysis, Selumetinib
- Where
- 16 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific…
- Conditions
- Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma
- Trial name
- NCT05544968
- Testing
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Medical College of Wisconsin
Lymphoma
Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy and peripheral stem cell transplantation may kill more tumor…
- Trial name
- NCT00002697
- Testing
- filgrastim, sargramostim, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255710
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Chronic Myeloid Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell…
- Conditions
- Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Diffuse Large Cell Lymphoma
- Trial name
- AlloTreo (NCT00598624)
- Testing
- Treosulfan IV
- Where
- 12 sites in Italy
- Volunteers
- 175 people
- Sponsor
- IRCCS San Raffaele
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT05645744
- Testing
- Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product.
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mustang Bio
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
This pilot phase II trial studies how well high dose cyclophosphamide, tacrolimus, and mycophenolate mofetil work in preventing graft versus host disease in patients with hematological malignancies undergoing myeloablative or…
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03128359
- Testing
- Busulfan, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- City of Hope Medical Center
Lymphoma
Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma
Patients with Diffuse Large B-cell Lymphoma with indication for palliative radiotherapy are treated with low-dose radiation (2 x 2 Gy) to the symptomatic sites only.
- Trial name
- NCT02803840
- Testing
- Low-dose radiotherapy
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase II trial to study the effectiveness of interleukin-12 in treating patients with previously treated non-Hodgkin's lymphoma or Hodgkin's disease.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT00003210
- Testing
- recombinant interleukin-12, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Chronic Myeloproliferative Disorders
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications.
- Conditions
- Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00006083
- Testing
- Fragmin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Richter's Transformation
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety…
- Trial name
- NCT02378038
- Testing
- PNT2258
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Relapsed Diffuse Large B-cell Lymphoma
Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant
Study of loncastuximab tesirine administered intravenously (IV) for maintenance therapy following autologous stem cell transplant in patients with relapsed diffuse large B cell lymphoma
- Trial name
- NCT05222438
- Testing
- loncastuximab tesirine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Non-Hodgkin Lymphoma
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
The purpose of this study is to determine the rate of response to the drugs bortezomib (Velcade) and vorinostat (Zolinza), when used in combination, in patients with relapsed (recurrent) and/or refractory (difficult to treat)…
- Trial name
- COMBOSTAT (NCT00837174)
- Testing
- Vorinostat in combination with Bortezomib
- Sponsor
- The Methodist Hospital Research Institute
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination, called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for…
- Conditions
- Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation
- Trial name
- NCT02481310
- Testing
- Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Diffuse Large B-Cell Lymphoma (DLBCL)
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
A Single-Arm, Open-Label, Multicenter Phase II Trial of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin) in Treating Elderly Patients with Previously Untreated Double-Positive Diffuse Large B-Cell Lymphoma
- Trial name
- NCT07397832
- Testing
- Chidamide, Rituximab, Polatuzumab Vedotin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134017
- Testing
- Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant…
- Conditions
- Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
- Trial name
- NCT02362997
- Testing
- Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 82 people
- Sponsor
- Dana-Farber Cancer Institute
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.
- Trial name
- NCT03939182
- Testing
- Abexinostat, Ibrutinib
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the…
- Trial name
- ARCHED (NCT05820841)
- Testing
- R-miniCHOP + Acalabrutinib, R-miniCHOP
- Where
- 17 sites in Germany
- Volunteers
- 330 people
- Sponsor
- Universität des Saarlandes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.